Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin

T. Colombo, I. Parisi, M. Zucchetti, C. Sessa, A. Goldhirsch, M. D'Incalci

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The combination of doxorubicin (Dx) with paclitaxel or docetaxel is clinically effective but there are concerns regarding the higher incidence of cardiotoxicity of the combination compared with Dx alone. The mechanism of the increased toxicity is still unclear. Purpose: To assess whether there is a pharmacokinetic interaction between paclitaxel, docetaxel or their vehicles and Dx in mice. Materials and methods: CDF1 male mice were treated with Dx either alone (10 mg/kg i.v.) or in combination with paclitaxel (25 mg/kg) or docetaxel (25 mg/kg) or their vehicles, i.e., cremophor-ethanol-glucose (cremophor) or polysorbate80-ethanol-glucose (polysorbate). Four mice were killed 4, 8 or 24 hours after Dx in each experimental group and Dx was assayed in serum and in heart, liver, kidney and spleen by HPLC. Results: Four hours after treatment the concentrations of Dx in heart, liver and kidney were much higher in mice concomitantly treated with paclitaxel, docetaxel (dissolved in either cremophor or polysorbate) and cremophor. At subsequent times the differences were modest and only reached statistical significance in a few cases. Dx metabolites were modified by concomitant treatment with taxanes or their vehicles. In particular, the levels of Dx aglycone in liver and kidney were significantly lower in mice treated with the combination than in mice given Dx alone. Conclusions: paclitaxel, docetaxel and cremophor when given together with Dx modify its distribution and metabolism, increasing Dx levels in many tissues including the heart. This might have some bearing on the toxicity of regimens in which Dx is combined with taxanes.

Original languageEnglish
Pages (from-to)391-395
Number of pages5
JournalAnnals of Oncology
Volume10
Issue number4
DOIs
Publication statusPublished - 1999

Keywords

  • Docetaxel
  • Doxorubicin
  • Interaction
  • Mice
  • Paclitaxel
  • Pharmacokinetics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin'. Together they form a unique fingerprint.

Cite this